Please login to the form below

Not currently logged in
Email:
Password:

Avita Medical appoints CEO

Dr Michael Perry joins from Novartis

Avita Medical has appointed Dr Michael Perry as its new chief executive officer at a time when the firm plans to submit its burn treatment ReCell to the FDA for review.

Perry has been a non-executive director for the Cambridge, UK-based regenerative medicine firm since February 2013 and previously served at Novartis in roles such as senior vice president and chief scientific officer, global business development and licensing, and chief scientific officer for its cell and gene therapy unit.

Prior to Novartis Perry was global head of R&D for the bioscience division at Baxter Healthcare, vice president of regulatory affairs for Sandoz Pharma, and president and CEO of cell and gene therapies for Novartis subsidiaries Systemix Inc. and Genetic Therapy Inc.

Lou Panaccio, chairman of Avita, said: “Mike’s expertise across the value chain in cell therapy along with his experience in business development, regulatory affairs and general management will be crucial to Avita’s future success.

“These fundamental attributes complemented by his US presence, will maximise Avita’s prospects as the company progresses through PMA submission, FDA review and preparation for large-scale product commercialisation.”

Perry succeeds Adam Kelliher after two years of service and will remain a consultant to the board of directors.

16th June 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics